HomeList of TitleSearchContact Us
Open Journal of Hematology

ISSN: 2075-907X
Volume 8, 2017

Discontinuation of imatinib after long term complete molecular response in patients with chronic myeloid leukemia diagnosed at late chronic phase

Lydie Ocini Ngolet*, Elira Dokekias A
Service d’Hématologie Clinique, CHU de Brazzaville- Congo, BP: 32

DOI: 10.13055/ojhmt_8_1_4.170715

Corresponding Address:
* Service d’Hématologie Clinique, CHU de Brazzaville- Congo, BP: 32; Email: lngolet@yahoo.fr

© Ngolet et al.; licensee Ross Science Publishers
open-access license: ROSS Open Access articles will be distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided that the original work will always be cited properly.

Article Processing History:
Receiving date: 22-4-2017
Acceptance date: 15-7-2017
Electronic publication date: 15-7-2017
Year of Publication: 2017

Imatinib is the first line therapy in chronic myeloid leukemia (CML) patients. It induces complete cytogenetic response (CCyR) to 75-90% of patients in early chronic phase [1]. Discontinuation is more and more offered as an option for prolonged complete molecular response (CMR) in patients diagnosed in early chronic phase [2, 3]. CML affects in Sub Saharan Africa a young population in reproductive age with desire of pregnancy. As imatinib is not indicated in pregnancy, imatinib discontinuation should be considered as a good therapeutic option for male and female patients in a desire of childbearing. However, would imatinib discontinuation an option for patients diagnosed in late chronic phase (CP) that achieve prolong complete molecular response?

We report the case of two patients that achieved respectively long term CCyr and long term CMR during a median of time of 71 months and relapsed shortly after discontinuation of the imatinib.

The first patient is a 24 years old woman diagnosed with late CP CML and high Sokal score at the age of 18. Imatinib was started at the dosage at 400mg daily. She achieved complete hematological response in 1 month (CHR), CCYr at 9 months and CMR at 12 months of therapy. She maintained them during 6 years (the molecular response was monitored every two years). At the age of 24, because she was pregnant; she decided on her own to discontinue the treatment and was loss of follow during 8 months. She came back to the hospital 8 months later with an enlarged spleen, major leukocytosis at 53G/L and slight anemia at 10g/dL.

The second patient is a 34 years old male that was diagnosed with late CP CML and high Sokal score. On imatinib at 400 mg daily, he achieved CHR at 2 months of therapy, CCYr at 8 months and CMR at 14 months. The patient was stable on imatinib during 8 years. Because he faced infertility issues that were for him related to the imatinib; he discontinued the imatinib and was loss of follow. He showed up 12 months later with enlarge spleen, loss a CHR, a leukocytosis at 98G/L and deep anemia at 7g/dl of hemoglobin.

Imatinib can be discontinued in patients exhibiting a prolonged complete molecular response [2]. For patients with CML and CCyR, it is clear now that prolonged CMR improves overtime [4]. However prolonged CMR is not the only criterion to indicate a discontinuation. These two cases suggest that discontinuation is not an option for patients that are diagnosed at late stage and have a high Sokal score. Indeed, despite long term CHR and CMR, relapses occurred rapidly after the imatinib discontinuation. The recurrence was linked to the cessation of the treatment since both of the patients attained again CHR when they restarted the imatinib, suggesting no resistance to the imatinib.

In such way, despite long term CMR, imatinib discontinuation should be examined carefully on patients with high Sokal score that were diagnosed at late CP.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


[1] Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J. High-dose imatinib therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004; 103: 2873–8. [PMID: 15070658] [DOI: 10.1182/blood-2003-11-3800]
[2] Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P. Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective , multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11: 1029–35. [DOI: 10.1016/S1470-2045(10)70233-3]
[3] Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K, Ohyashiki K. Discontinuation of Imatinib in Japanese Patients with Chronic Myeloid Leukemia. Haematologica. 2012; 97: 903–6. [PMID: 22180435] [PMCID: PMC3366657] [DOI: 10.3324/haematol.2011.056853]
[4] Goldman JM, Hugues T, Radich J, Branford S, Hocchaus A, So S, et al. Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib (IM) in the IRIS study. Blood. 2005; 106: 51a.
2017 Ross Science Publishers